Li Zongjin, Han Zhongchao, Wu Joseph C
The Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA 94305, USA.
J Cell Biochem. 2009 Feb 1;106(2):194-9. doi: 10.1002/jcb.22003.
Using endothelial cells for therapeutic angiogenesis/vasculogenesis of ischemia diseases has led to exploring human embryonic stem cells (hESCs) as a potentially unlimited source for endothelial progenitor cells. With their capacity for self-renewal and pluripotency, hESCs and their derived endothelial cells (hESC-ECs) may be more advantageous than other endothelial cells obtained from diseased populations. However, hESC-ECs' poor differentiation efficiency and poorly characterized in vivo function after transplantation present significant challenges for their future clinical application. This review will focus on the differentiation pathways of hESCs and their therapeutic potential for vascular diseases, as well as the monitoring of transplanted cells' fate via molecular imaging. Finally, cell enhancement strategies to improve the engraftment efficiency of hESC-ECs will be discussed.
利用内皮细胞进行缺血性疾病的治疗性血管生成/血管发生，促使人们探索将人类胚胎干细胞（hESCs）作为内皮祖细胞的潜在无限来源。凭借其自我更新和多能性的能力，hESCs及其衍生的内皮细胞（hESC-ECs）可能比从患病群体中获得的其他内皮细胞更具优势。然而，hESC-ECs的低分化效率以及移植后体内功能特征不明确，对其未来临床应用构成了重大挑战。本综述将聚焦于hESCs的分化途径及其对血管疾病的治疗潜力，以及通过分子成像监测移植细胞的命运。最后，将讨论提高hESC-ECs植入效率的细胞增强策略。
